Sk Biopharmaceuticals Co., Ltd. (326030) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sk Biopharmaceuticals Co., Ltd. (326030:KRX), powered by AI.

Current Price
₩90,200
P/E Ratio
26.5
Market Cap
7.1T
Sector
Healthcare
What is the Sk Biopharmaceuticals Co., Ltd. stock price forecast?

Sk Biopharmaceuticals Co., Ltd. is currently trading at ₩90,200. View real-time AI analysis on Alpha Lenz.

What is Sk Biopharmaceuticals Co., Ltd. insider trading activity?

View the latest insider trading data for Sk Biopharmaceuticals Co., Ltd. on Alpha Lenz.

What is Sk Biopharmaceuticals Co., Ltd.'s P/E ratio?

Sk Biopharmaceuticals Co., Ltd.'s P/E ratio is 26.5.

Sk Biopharmaceuticals Co., Ltd.

KRX · 326030
₩90,200+2,300(+2.62%)Market closedKRX regular session 09:00–15:30 KST
Ask about Sk Biopharmaceuticals Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Sk Biopharmaceuticals Co., Ltd. trades at a P/E of 26.5 (premium valuation) with strong ROE of 39.3%. 3Y revenue CAGR of 42.1% highlights clear growth momentum.

Ask for details

Company Overview

Sk Biopharmaceuticals Co., Ltd. is a leading biomedical company primarily engaged in the research, development, and commercialization of innovative pharmaceutical products. This company operates with a strong focus on central nervous system (CNS) disorders, aiming to address unmet medical needs through its proprietary drug development programs. One of its notable achievements includes the development of therapies for epilepsy and Parkinson's disease, which highlights its commitment to advancing treatments in the CNS sector. Additionally, Sk Biopharmaceuticals is actively expanding its portfolio through strategic partnerships and collaborations in the biopharmaceutical industry. By leveraging advanced research facilities and a robust pipeline of clinical stage assets, the company plays a significant role in contributing to the pharmaceutical market's landscape. Its presence is crucial in enhancing the availability of targeted therapies, ultimately improving patient outcomes across global healthcare systems.

CEO이동훈
SectorHealthcare
IndustryBiotechnology
Employees246

Company Statistics

FY 2025

Profile

₩7,063,855,150,000Market Cap
₩706,740,960,300Revenue
78.31MShares Out
246Employees

Margins

93.93%Gross
25.94%EBITDA
28.86%Operating
21.35%Pre-Tax
35.83%Net

Valuation

26.46P/E
8.69P/B
9.99EV/Sales
37.19EV/EBITDA
48.11P/FCF

Growth (CAGR)

42.12%Rev 3Yr
93.58%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

22.66%ROA
39.28%ROE
14.19%ROIC

Financial Health

₩307,770,519,300Cash & Cash Equivalents
₩64,268,530,400Net Debt
45.03%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Sk Biopharmaceuticals Co., Ltd. (ticker: 326030) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 246 employees. Market cap is $7.1T.

The current price is ₩90,200 with a P/E ratio of 26.46x and P/B of 8.69x.

ROE is 39.28% and operating margin is 28.86%. Annual revenue is $706.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Sk Biopharmaceuticals Co., Ltd. (326030) Stock Forecast 2026 ₩90,200 — Price, Financials & Analyst Targets | Alpha Lenz